• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Safety Signal Evaluation of a Risk of Syncope and Dizziness Not Related to Bleeding or Stroke in Direct Oral Anticoagulant-Treated Patients
Clin Ther. 2023 Jan 16:S0149-2918(22)00416-7. doi: 10.1016/j.clinthera.2022.12.010. Online ahead of print.ABSTRACTPURPOSE: In clinical studies, rivaroxaban treatment has been associated with increased incidence of syncope not related to bleeding, anemia, or stroke. The study objective was to evaluate the occurrence of dizziness and/or syncope not related to bleeding, anemia, or stroke in patients treated with direct oral anticoagulants (DOACs).METHODS: A retrospective, observational, comparative study of adult patients diagnosed with atrial fibrillation and treated with DOACs was conducted using digital retrieval of medica...
Source: Clinical Therapeutics - January 18, 2023 Category: Drugs & Pharmacology Authors: Ophir Lavon Daisy Cohen Source Type: research

Stroke and bleeding risks in patients with atrial fibrillation treated with reduced apixaban dose: a real life study.
Abstract Our objective was to assess the association between reduced apixaban dose and two outcomes: ischemic stroke/systemic embolism (SE) and major bleeding. We performed a retrospective cohort study within the database of the largest healthcare provider in Israel. We identified all patients diagnosed with atrial fibrillation, who started apixaban treatment between 2013 and 2017. Apixaban users were classified into three dosing regimen groups based on their renal function, age and weight: standard dose (5 mg bid), adjusted reduced dose (2.5 mg bid), and underdosing (2.5 mg bid). Patients were followed through 2...
Source: Clinical Pharmacology and Therapeutics - June 18, 2020 Category: Drugs & Pharmacology Authors: Salameh M, Gronich N, Stein N, Kotler A, Rennert G, Auriel E, Saliba W Tags: Clin Pharmacol Ther Source Type: research